Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJingxin Li, Tao Zhu, Hongxing Pan et al.|The Lancet Respiratory Medicine|2022Cited by 172
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Fengcai Zhu, Rong Tang et al.|Emerging Microbes & Infections|2022Cited by 30
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previouslyLairun Jin, Fengcai Zhu, Rong Tang et al.|medRxiv|2022Cited by 10
Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control TrialJingxin Li, Fengcai Zhu, Shipo Wu et al.|SSRN Electronic Journal|2022Cited by 1